AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon (NYSE:BBLN) is set to join the broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective after the US market opens on June 27, according to a preliminary list of additions posted June 3. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as … [Read more…]
TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) today announced that the first patient was dosed in the global TROPION-Breast02 phase 3 trial evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus investigator’s choice of chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) not eligible … [Read more…]
Joseph M. Patti, Ph.D., Appointed President and CEO John J. Kaiser, Retires as CEO, Remains as Board Director RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Evecxia Therapeutics, a clinical stage biopharmaceutical company dedicated to realizing the therapeutic potential of serotonin synthesis amplification for the treatment of brain disorders, today announced that Joseph M. Patti, Ph.D., has been appointed … [Read more…]
Lauren Cohen Recently Joined as Vice President of Marketing and Communications NEWTON, Mass.–(BUSINESS WIRE)–, June 13, 2022 —Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced it is building a commercial team to prepare for market launch of the Lumicell Direct Visualization System (DVS), which includes its … [Read more…]
Expanded relationship will build upon established processes initiated in 2019 to meet ASC Therapeutics clinical program WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL #LIFEatCRL–Charles River Laboratories International, Inc. (NYSE: CRL) and ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of transformative in vivo gene replacement, gene editing and allogeneic cell therapies, today announced they have agreed to … [Read more…]
ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its next-generation ALLY Adaptive Cataract Treatment System (“ALLY” or “ALLY System”). ALLY is the first FDA-cleared platform … [Read more…]
BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that company management will present its corporate highlights at the JMP Securities Life Sciences Conference, June 16, 2022 with a presentation at 2:00 p.m. ET in New … [Read more…]
Following Additional Data Submission to FDA Demonstrating ORR Superiority Over Ibrutinib As Determined by IRC, PDUFA Goal Date Extended to January 20, 2023 to Allow Time for Review CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to … [Read more…]
Health Canada decision signifies the first global regulatory approval for Amylyx and the first new therapy for ALS approved in Canada since 2018 ALBRIOZA (also known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy or when added to existing treatments In a clinical trial, ALBRIOZA … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Anesthesia and Respiratory Devices Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. The report on the global anesthesia and respiratory devices market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of … [Read more…]
